Species Differences in Troxacitabine Pharmacokinetics and Pharmacodynamics
- 15 November 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (22) , 7692-7702
- https://doi.org/10.1158/1078-0432.ccr-04-0657
Abstract
Purpose: Troxacitabine is the first unnatural l-nucleoside analog to show potent preclinical antitumor activity and is currently under clinical investigation. Significant differences in troxacitabine toxicity between mice, rats, monkeys, and humans were observed during preclinical and clinical evaluations. To better understand the different toxicity and efficacy results observed between the human xenograft mouse tumor models used for preclinical assessment and the clinical study results, the pharmacodynamics and pharmacokinetics of troxacitabine were reassessed in murine and human models.Keywords
This publication has 27 references indexed in Scilit:
- Novel Role of 3-Phosphoglycerate Kinase, a Glycolytic Enzyme, in the Activation of L-Nucleoside Analogs, a New Class of Anticancer and Antiviral AgentsJournal of Biological Chemistry, 2003
- Phase II Study of Troxacitabine (BCH-4556) in Patients With Advanced and/or Metastatic Renal Cell Carcinoma: A Trial of the National Cancer Institute of Canada-Clinical Trials GroupJournal of Clinical Oncology, 2003
- Phosphorylation of Pyrimidine l-Deoxynucleoside Analog DiphosphatesJournal of Biological Chemistry, 2002
- Phase I and Pharmacokinetic Study of Novel l-Nucleoside Analog Troxacitabine Given as a 30-Minute Infusion Every 21 DaysJournal of Clinical Oncology, 2002
- A Novel Action of Human Apurinic/Apyrimidinic EndonucleaseJournal of Biological Chemistry, 2000
- L- and D-Enantiomers of 2′,3′-Dideoxycytidine 5′-Triphosphate Analogs as Substrates for Human DNA PolymerasesJournal of Biological Chemistry, 1995
- Structure-Activity Relationships Among a New Class of Antiviral Heterosubstituted 2',3'-Dideoxynucleoside AnaloguesNucleosides, Nucleotides and Nucleic Acids, 1995
- Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2?-deoxyadenosineCancer Chemotherapy and Pharmacology, 1995
- Species Differences in Nucleotide Pool Levels of 2′,3′-Dideoxycytidine: A Possible Explanation for Species-Specific ToxicityToxicology and Applied Pharmacology, 1993
- Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell LinesJNCI Journal of the National Cancer Institute, 1991